financetom
Business
financetom
/
Business
/
Gates Industrial misses Q3 sales estimates, announces $300 mln buyback
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Gates Industrial misses Q3 sales estimates, announces $300 mln buyback
Oct 29, 2025 5:30 AM

Overview

* Gates Industrial ( GTES ) Q3 net sales up 3% yr/yr, missing analyst expectations

* Adjusted EPS beats analyst estimates for Q3 2025

* Company announces $300 mln share repurchase authorization

Outlook

* Gates Industrial ( GTES ) raises 2025 adjusted EPS guidance towards high end of prior range

* Company expects 2025 core sales growth of 0.5% to 1.5%

* Gates Industrial ( GTES ) anticipates 2025 adjusted EBITDA of $770 mln to $790 mln

Result Drivers

* AUTOMOTIVE REPLACEMENT - Co cites solid growth in Automotive Replacement as a key driver for sales improvement

* PERSONAL MOBILITY - Strong growth in Personal Mobility contributed to sales increase

* COST OPTIMIZATION - Improved adjusted EBITDA margin attributed to structural cost reduction initiatives

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Sales Miss $855.70 $861.10

mln mln (8

Analysts

)

Q3 Beat $0.39 $0.37

Adjusted (11

EPS Analysts

)

Q3 EPS $0.31

Q3 Net $81.60

Income mln

Q3 Beat $195.80 $195.30

Adjusted mln mln (8

EBITDA Analysts

)

Q3 Net $88.70

Income mln

continui

ng

operatio

ns

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

* Wall Street's median 12-month price target for Gates Industrial Corporation PLC ( GTES ) is $30.00, about 13.9% above its October 28 closing price of $25.82

* The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Form 8.3 - Bakkavor Group PLC
Form 8.3 - Bakkavor Group PLC
Sep 23, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Midland Exploration Starts Follow Up Program On Its New Discovery Of Gold-Zinc-Silver Mineralization at Caniapisc Au Project
Midland Exploration Starts Follow Up Program On Its New Discovery Of Gold-Zinc-Silver Mineralization at Caniapisc Au Project
Sep 23, 2025
09:29 AM EDT, 09/23/2025 (MT Newswires) -- Midland Exploration ( MIDLF ) announced Tuesday the start of a follow-up exploration program on its new discovery of gold, zinc, and silver on its Caniapisc Au project, in the Eeyou Istchee James Bay and Caniapiscau regions, and also announced map designation of two new projects in the same area. A statement noted...
Solid Biosciences Signs Licensing Deal With Kinea Bio for AAV-SLB101 to Treat Muscular Dystrophy
Solid Biosciences Signs Licensing Deal With Kinea Bio for AAV-SLB101 to Treat Muscular Dystrophy
Sep 23, 2025
08:31 AM EDT, 09/23/2025 (MT Newswires) -- Solid Biosciences ( SLDB ) said Tuesday that it has signed a non-exclusive licensing and collaboration agreement with Kinea Bio to use Solid Biosciences' ( SLDB ) proprietary AAV-SLB101 to treat muscle tropism and reduced liver uptake. Under the terms of the deal, Solid has granted Kinea Bio a non-exclusive worldwide license to...
Pattern Group Closes IPO
Pattern Group Closes IPO
Sep 23, 2025
08:30 AM EDT, 09/23/2025 (MT Newswires) -- Pattern Group ( PTRN ) said Tuesday it has completed its initial public offering of series A common shares. The offering consisted of about 10 million series A common shares sold by the company and an equal number of shares sold by certain selling stockholders. Pattern did not receive any proceeds from the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved